Novel Dihydropyridin-2(1H)-One Compounds as S-Nitrosoglutathione Reductase Inhibitors and Neurokinin-3 Receptor Antagonists

The compound of formula I or pharmaceutically acceptable salts thereof:

• wherein
• X is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl, each having 6 members or less in the ring;
• Y is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, and substituted heterocyclyl;
• Z is selected from the group consisting of O, S, and NR7;
• R1 and R2 and R7 are independently selected from the group consisting of hydrogen, and C1-C6 alkyl;
• R3 is selected from the group consisting of hydrogen, nitro, cyano, carboxyl, carbamoyl, methylsulfonamido, fluoro, chloro, bromo, hydroxy, methylsulfonyl, and methylsulfinyl, isoxazol-4-yl, C1-C6 alkoxy, —C(NH)NHOH, sulfonic acid, and acetyl;
• R4 is selected from the group consisting of hydrogen, hydroxyl, methoxy, carboxyl, and tetrazol-5-yl;
• wherein, when R3, is hydrogen, then R4 is not hydrogen;
• or optionally R3 and R4, taken together can form a heterocycle;
• and
• R5 is selected from the group consisting of hydrogen, hydroxyl, carboxy, chloro, fluoro, cyano, —O(CH2)1-6NMe2, C1-C6 alkyl, —O(CH2)1-6OCH3, —O(CH2)1-6OH, acetyl, CF3, and C1-C6 alkoxy;
• or optionally R4 and R5, taken together can form a heterocycle;
• and
• R6 is selected from the group consisting of hydrogen and hydroxyl.